Early symptomatic phase Alzheimer's disease
Conditions
Brief summary
Proportion of patients with adverse events after 1 year as a measure of safety and tolerability, and number of subjects who comply with the research protocol as a measure of feasibility.
Detailed description
Change in performance in the CERAD 10 word Test Change in the Mini-Mental State Examination (MMSE) score Change in performance in Trail-Making test A and B Change in scores in other cognitive tests: the Clock Drawing Test, Controlled Oral Word Association Test (COWAT)-FAS, Visual Object and Space Perception (VOSP) Silhouettes Change in Clinical Dementia Rating Scale Global score
Interventions
DRUGSaline (NaCl)
DRUGSALINE
DRUGOTHER PLASMA PROTEIN FRACTIONS
DRUGOctaplasma 45-70 mg/ml pulver og væske til infusjonsvæske
DRUGoppløsning
Sponsors
Norwegian University Of Science And Technolology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with adverse events after 1 year as a measure of safety and tolerability, and number of subjects who comply with the research protocol as a measure of feasibility. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in performance in the CERAD 10 word Test Change in the Mini-Mental State Examination (MMSE) score Change in performance in Trail-Making test A and B Change in scores in other cognitive tests: the Clock Drawing Test, Controlled Oral Word Association Test (COWAT)-FAS, Visual Object and Space Perception (VOSP) Silhouettes Change in Clinical Dementia Rating Scale Global score | — |
Countries
Norway
Outcome results
None listed